Short-Term Efficacy and Long-Term Tolerability of Omidenepag Isopropyl 0.002% Ophthalmic Solution in Korean Glaucoma Patients

Purpose: To retrospectively investigate the short-term intraocular pressure (IOP)-lowering efficacy and long-term tolerability of omidenepag isopropyl 0.002% ophthalmic solution (OMDI) in Korean patients with primary open-angle glaucoma (POAG) in a real-world setting.Methods: This study included POAG patients who were prescribed OMDI between June 2021 and December 2022.OMDI was administered as naïve monotherapy, switching monotherapy, or concomitant additional therapy.Changes in IOP and adverse drug reactions were recorded.Results: Of a total of 216 eyes, 33, 52, and 131 were administered OMDI as naïve monotherapy, switching monotherapy, and concomitant additional therapy, respectively.The IOP decreased significantly from 14.6 ± 3.4 mmHg to 13.2 ± 2.9 mmHg at 4 weeks after OMDI treatment in all participants (p < 0.001).The pre-and post-treatment IOPs were comparable in the switching therapy group (p = 0.069), whereas the post-treatment IOP was significantly lower in the naïve and concomitant therapy groups compared to the pre-treatment IOP (all p < 0.001).Adverse reactions were reported in 55.56% of patients (n = 120).Ocular hyperemia was the most common adverse reaction (n = 102, 47.22%).The 1-year persistence rate of OMDI was 65.74%, and the most common reason for discontinuation was insufficient lowering of IOP (n = 24, 32.43%).Conclusions: In Korean POAG patients, the IOP was significantly lowered at 1 month after OMDI use.However, discontinuation was relatively common with long-term use, which was mainly due to insufficient IOP lowering.Conjunctival hyperemia was common but well-tolerated among patients.